- Rhythm Biosciences (RHY) has confirmed its network of clinicians is the latest group to join the company’s clinical trial for ColoSTAT
- CliniTrials, a network of clinicians with a centralised administration, will be joining the trial for ColoSTAT, a blood test for the detection of colorectal cancer
- ColoSTAT is intended to be an affordable, minimally invasive blood test for early detection of bowel cancer for the global mass market
- With over twenty years of experience, CliniTrials represents up to six sites in Western Australia, including large patient populations across Perth, Mandurah and Busselton
- The first patients have now been recruited for the trial
- Rhythm Biosciences is down 1.26 per cent, trading at $1.18
Rhythm Biosciences (RHY) has confirmed its network of clinicians is the latest group to join the company’s clinical trial for ColoSTAT.
Rhythm Biosciences is a predictive diagnostics company, specialising in early cancer detection. Over 850,000 people die from colorectal cancer each year, with colorectal cancer typically diagnosed at a later stage.
CliniTrials, a network of clinicians with a centralised administration, will be joining the trial for ColoSTAT, a blood test for the detection of colorectal cancer, aimed at global mass market screening.
ColoSTAT is intended to be a simple, affordable, minimally invasive blood test for early detection of bowel cancer for the global mass market. It is expected to meet the current standard of care, the faecal immunochemical test, but at a lower cost, while being accessible by those who cannot use standard screening programs.
With over twenty years of experience, CliniTrials represents up to six sites in Western Australia, including large patient populations across Perth, Mandurah and Busselton. The company says clinicians at both GP and family practice level are connected with their patients at these locations, making them well placed to identify those people that could participate in the trial.
“The addition of CliniTrials in Perth further extends the geographic diversification of our clinical trial for our lifesaving colorectal cancer detection technology, ColoSTAT,” said Rhythm CEO Glenn Gilbert.
“The technology that underpins ColoSTAT will transform the way we screen for colorectal cancer globally. We have demonstrated it to be highly accurate and are focused on working with our partners to complete the clinical trial and deliver ColoSTAT to market.”
The first patients have now been recruited for the trial.
Rhythm Biosciences is down 1.26 per cent, trading at $1.18 at 2:10 pm AEST.